Refining Endpoint Measures in Clinical Trials for Hypertrophic Cardiomyopathy: The Emerging Role of Patient-Reported Outcomes
- PMID: 35902156
- DOI: 10.1016/j.jchf.2022.04.002
Refining Endpoint Measures in Clinical Trials for Hypertrophic Cardiomyopathy: The Emerging Role of Patient-Reported Outcomes
Keywords: endpoints; hypertrophic cardiomyopathy; patient-reported outcomes.
Conflict of interest statement
Funding Support and Author Disclosures Dr Rowin has received research grant support from Pfizer. Dr Maron has served as a steering committee member for Cytokinetics, Imbria Pharmaceuticals, and Takeda Pharmaceuticals; and has received research grant support from Takeda Pharmaceuticals.
Comment on
-
Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic Cardiomyopathy.JACC Heart Fail. 2022 Aug;10(8):531-539. doi: 10.1016/j.jchf.2022.03.002. Epub 2022 May 4. JACC Heart Fail. 2022. PMID: 35902155
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
